S&P 500   3,298.39 (+0.11%)
DOW   26,741.71 (+0.29%)
QQQ   269.61 (+0.09%)
AAPL   439.53 (+0.87%)
MSFT   212.66 (-1.79%)
FB   249.97 (-0.79%)
GOOGL   1,471.72 (-0.74%)
AMZN   3,127.63 (+0.51%)
NVDA   445.77 (+1.22%)
CGC   19.08 (+0.10%)
BABA   262.34 (+1.71%)
TSLA   1,478.68 (-0.43%)
MU   50.92 (+1.05%)
GE   6.16 (+0.65%)
AMD   84.61 (+8.94%)
T   29.95 (+1.11%)
F   6.80 (+1.49%)
ACB   10.63 (+2.01%)
GILD   70.57 (-1.62%)
NFLX   507.91 (+1.86%)
DIS   117.96 (+1.38%)
BAC   25.01 (+0.08%)
BA   164.92 (+1.63%)
S&P 500   3,298.39 (+0.11%)
DOW   26,741.71 (+0.29%)
QQQ   269.61 (+0.09%)
AAPL   439.53 (+0.87%)
MSFT   212.66 (-1.79%)
FB   249.97 (-0.79%)
GOOGL   1,471.72 (-0.74%)
AMZN   3,127.63 (+0.51%)
NVDA   445.77 (+1.22%)
CGC   19.08 (+0.10%)
BABA   262.34 (+1.71%)
TSLA   1,478.68 (-0.43%)
MU   50.92 (+1.05%)
GE   6.16 (+0.65%)
AMD   84.61 (+8.94%)
T   29.95 (+1.11%)
F   6.80 (+1.49%)
ACB   10.63 (+2.01%)
GILD   70.57 (-1.62%)
NFLX   507.91 (+1.86%)
DIS   117.96 (+1.38%)
BAC   25.01 (+0.08%)
BA   164.92 (+1.63%)
S&P 500   3,298.39 (+0.11%)
DOW   26,741.71 (+0.29%)
QQQ   269.61 (+0.09%)
AAPL   439.53 (+0.87%)
MSFT   212.66 (-1.79%)
FB   249.97 (-0.79%)
GOOGL   1,471.72 (-0.74%)
AMZN   3,127.63 (+0.51%)
NVDA   445.77 (+1.22%)
CGC   19.08 (+0.10%)
BABA   262.34 (+1.71%)
TSLA   1,478.68 (-0.43%)
MU   50.92 (+1.05%)
GE   6.16 (+0.65%)
AMD   84.61 (+8.94%)
T   29.95 (+1.11%)
F   6.80 (+1.49%)
ACB   10.63 (+2.01%)
GILD   70.57 (-1.62%)
NFLX   507.91 (+1.86%)
DIS   117.96 (+1.38%)
BAC   25.01 (+0.08%)
BA   164.92 (+1.63%)
S&P 500   3,298.39 (+0.11%)
DOW   26,741.71 (+0.29%)
QQQ   269.61 (+0.09%)
AAPL   439.53 (+0.87%)
MSFT   212.66 (-1.79%)
FB   249.97 (-0.79%)
GOOGL   1,471.72 (-0.74%)
AMZN   3,127.63 (+0.51%)
NVDA   445.77 (+1.22%)
CGC   19.08 (+0.10%)
BABA   262.34 (+1.71%)
TSLA   1,478.68 (-0.43%)
MU   50.92 (+1.05%)
GE   6.16 (+0.65%)
AMD   84.61 (+8.94%)
T   29.95 (+1.11%)
F   6.80 (+1.49%)
ACB   10.63 (+2.01%)
GILD   70.57 (-1.62%)
NFLX   507.91 (+1.86%)
DIS   117.96 (+1.38%)
BAC   25.01 (+0.08%)
BA   164.92 (+1.63%)
Log in

OTCMKTS:DSNKYDAIICHI SANKYO/S Stock Price, Forecast & News

$87.26
-1.05 (-1.19 %)
(As of 08/4/2020 01:40 PM ET)
Add
Compare
Today's Range
$86.94
Now: $87.26
$89.27
50-Day Range
$77.11
MA: $82.13
$91.87
52-Week Range
$48.34
Now: $87.26
$93.70
Volume8,900 shs
Average Volume12,634 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, and markets pharmaceutical products worldwide. The company offers prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone compilations; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimer's disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. It also provides olmesartan and Telmisartan antihypertensive agents; levofloxacin, an antibacterial agent; pravastatin and Rosuvastatin antihyperlipidemic agents; iohexol to enhance the visibility of diagnostic X-ray imaging; loxoprofen, an anti-inflammatory analgesic; and naloxegol for opioid-induced constipation treatment. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a cold remedy; Loxonin S, an anti-inflammatory analgesic; Transino for treating melisma/alleviating spots, freckles, and pigmentation; Minon, a moisturizing cleanser; and Clean Dental, an oral care product. Additionally, the company offers Influenza HA Vaccine; Rotarix Oral Liquid, a vaccine for prevention of rotavirus; ActHIB, a haemophilus influenzae type b vaccine; Live Attenuated Measles-Rubella Combined Vaccine; and Squarekids, a vaccine for the prevention of pertussis, diphtheria, tetanus, and poliomyelitis. It also offers pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration agreements with Roche for the development of a HER2 diagnostic test; Sarah Cannon Research Institute to develop novel cancer therapies; and Integral Molecular, Inc. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceuticals: Other
Sub-IndustryN/A
Current SymbolOTCMKTS:DSNKY
CUSIPN/A
CIKN/A
Phone(136) 225-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14,446
Next Earnings DateN/A
OptionableNot Optionable
$87.26
-1.05 (-1.19 %)
(As of 08/4/2020 01:40 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DSNKY News and Ratings via Email

Sign-up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DAIICHI SANKYO/S (OTCMKTS:DSNKY) Frequently Asked Questions

How has DAIICHI SANKYO/S's stock been impacted by COVID-19 (Coronavirus)?

DAIICHI SANKYO/S's stock was trading at $57.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DSNKY shares have increased by 51.1% and is now trading at $87.26.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of DAIICHI SANKYO/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DAIICHI SANKYO/S in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for DAIICHI SANKYO/S
.

What guidance has DAIICHI SANKYO/S issued on next quarter's earnings?

DAIICHI SANKYO/S issued an update on its FY 2021 Pre-Market earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of 0.80-0.80 for the period. The company issued revenue guidance of $9.021-9.021 billion.

Has DAIICHI SANKYO/S been receiving favorable news coverage?

Media stories about DSNKY stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DAIICHI SANKYO/S earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the next several days.
View the latest news about DAIICHI SANKYO/S
.

Who are some of DAIICHI SANKYO/S's key competitors?

Who are DAIICHI SANKYO/S's key executives?

DAIICHI SANKYO/S's management team includes the following people:
  • Mr. Joji Nakayama, Chairman & Global CEO (Age 69)
  • Mr. Sunao Manabe, Pres, COO & Representative Director (Age 65)
  • Mr. Toshiaki Sai, CFO, Exec. VP, Head of Corp. Strategy & Management Division and Representative Director
  • Mr. Junichi Onuma, Sr. Director of IR Group
  • Mr. Yoshihiro Aoyagi, Head of Corp. Affairs Division, Exec. Officer & Gen. Counsel

What is DAIICHI SANKYO/S's stock symbol?

DAIICHI SANKYO/S trades on the OTCMKTS under the ticker symbol "DSNKY."

How do I buy shares of DAIICHI SANKYO/S?

Shares of DSNKY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DAIICHI SANKYO/S's stock price today?

One share of DSNKY stock can currently be purchased for approximately $87.26.

What is DAIICHI SANKYO/S's official website?

The official website for DAIICHI SANKYO/S is www.daiichisankyo.com.

How can I contact DAIICHI SANKYO/S?

The company can be reached via phone at (136) 225-1111.

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.